Oncternal Therapeutics Inc. [NASDAQ: ONCT] slipped around -1.5 points on Monday, while shares priced at $6.76 at the close of the session, down -18.16%. The company report on April 13, 2021 that Oncternal Therapeutics Announces Appointment of Chase Leavitt as General Counsel.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced the appointment of Chase Leavitt as General Counsel. Mr. Leavitt joins the Company with extensive experience providing strategic, transactional, financial, and operational advice to life sciences companies.
“Chase is a highly seasoned and pragmatic General Counsel and business leader with a broad background spanning both biotech and technology companies that will help to position Oncternal for our next stage of growth,” said James Breitmeyer, M.D., Ph.D., Oncternal’s President and CEO.
Oncternal Therapeutics Inc. stock is now 37.96% up from its year-to-date (YTD) trading value. ONCT Stock saw the intraday high of $7.68 and lowest of $6.6601 per share. The company’s 52-week high price is 10.56, which means current price is +50.22% above from all time high which was touched on 04/07/21.
Compared to the average trading volume of 1.71M shares, ONCT reached a trading volume of 3153401 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Oncternal Therapeutics Inc. [ONCT]?
Oppenheimer have made an estimate for Oncternal Therapeutics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on April 07, 2021. While these analysts kept the previous recommendation, Northland Capital raised their target price to Outperform. The new note on the price target was released on February 23, 2021, representing the official price target for Oncternal Therapeutics Inc. stock.
The Average True Range (ATR) for Oncternal Therapeutics Inc. is set at 0.98, with the Price to Sales ratio for ONCT stock in the period of the last 12 months amounting to 110.80. The Price to Book ratio for the last quarter was 1.77.
How has ONCT stock performed recently?
Oncternal Therapeutics Inc. [ONCT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -18.06. With this latest performance, ONCT shares gained by 6.12% in over the last four-week period, additionally plugging by 267.39% over the last 6 months – not to mention a rise of 141.43% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ONCT stock in for the last two-week period is set at 41.81, with the RSI for the last a single of trading hit 35.30, and the three-weeks RSI is set at 45.63 for Oncternal Therapeutics Inc. [ONCT]. The present Moving Average for the last 50 days of trading for this stock 7.36, while it was recorded at 8.48 for the last single week of trading, and 4.17 for the last 200 days.
Oncternal Therapeutics Inc. [ONCT]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Oncternal Therapeutics Inc. [ONCT] shares currently have an operating margin of -519.76. Oncternal Therapeutics Inc.’s Net Margin is presently recorded at -510.37.
Return on Total Capital for ONCT is now -27.52, given the latest momentum, and Return on Invested Capital for the company is -27.05. Return on Equity for this stock declined to -27.07, with Return on Assets sitting at -24.51. When it comes to the capital structure of this company, Oncternal Therapeutics Inc. [ONCT] has a Total Debt to Total Equity ratio set at 0.04. Additionally, ONCT Total Debt to Total Capital is recorded at 0.04, with Total Debt to Total Assets ending up at 0.03.
Reflecting on the efficiency of the workforce at the company, Oncternal Therapeutics Inc. [ONCT] managed to generate an average of -$1,230,357 per employee.Oncternal Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 20.10 and a Current Ratio set at 20.10.
Earnings analysis for Oncternal Therapeutics Inc. [ONCT]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ONCT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Oncternal Therapeutics Inc. go to 0.00%.
Insider trade positions for Oncternal Therapeutics Inc. [ONCT]
There are presently around $57 million, or 21.70% of ONCT stock, in the hands of institutional investors. The top three institutional holders of ONCT stocks are: VANGUARD GROUP INC with ownership of 1,681,504, which is approximately 504.193% of the company’s market cap and around 14.82% of the total institutional ownership; IKARIAN CAPITAL, LLC, holding 1,030,323 shares of the stock with an approximate value of $6.96 million in ONCT stocks shares; and 683 CAPITAL MANAGEMENT, LLC, currently with $4.93 million in ONCT stock with ownership of nearly New of the company’s market capitalization.
Positions in Oncternal Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 44 institutional holders increased their position in Oncternal Therapeutics Inc. [NASDAQ:ONCT] by around 7,364,019 shares. Additionally, 9 investors decreased positions by around 3,154,514 shares, while 8 investors held positions by with 2,098,487 shares. The mentioned changes placed institutional holdings at 8,420,046 shares, according to the latest SEC report filing. ONCT stock had 35 new institutional investments in for a total of 5,182,956 shares, while 6 institutional investors sold positions of 2,728,366 shares during the same period.